research reports and media, page-1606

Thanks for the update Bre Wolf. I myself am getting more and more excited with this news.

one of the things that jumps out at me from the release today and as echoed in coppo's post is that they are so limited in supply due to trials that they have to limit how much PPS can be used for SAS. now is this because the drug costs money and PAR are trying to reduce costs and keep it low or is it that there is hardly ability to produce the product?


This is where I assume a distribution deal with a big player comes in and helps out with the supply chain and logistics? If we can get a distribution deal, is bene capable of ramping up stock round the world?